Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$66.61
▼ $0.70 (-1.0%)
Market data updated: 09/20 07:36 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/20/2026
Market Cap
$13.02B
Day Range
$66.10 - $67.56
52-Week Range
$48.78 - $93.42
Beta
—
Next Earnings
27.10.2026
Support
$66.10
Resistance
$91.00
BBIO is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+24.9% (1Y)
Strengths: 10/31 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 126.3%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$67.06 vs. price $66.61 (-200.7%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
45
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
51
Quality
63
Value
38
Momentum
10
Risk
62
Sentiment
92
Fundamental
51
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of BridgeBio Pharma has centered on its promising clinical progress with **acoramidis** in transthyretin amyloid cardiomyopathy (ATTR-CM), highlighting potential cardiac structural and functional improvements in Phase 3 trial data. The company also announced new research on **infigratinib’s impact on achondroplasia complications** at a major pediatric endocrinology conference. Additionally, BridgeBio was included in a U.S. government drug pricing deal aimed at expanding patient access and lowering costs, while analysts maintained a bullish outlook with a $120 price target.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about BridgeBio Pharma, Inc.. News trend score: 92. Reason: 8 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
42
🎯 Conviction (vs. Emotion)
52
Psychology
85
Fundamentals
51
Technical
10
Valuation
38
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
+1%
Market Narrative
49
Fundamental Reality
52
Narrative Gap
-3
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
Market behavior suggests traders are fixated on the 1.0% support level, consistent with anchoring bias. The extreme positive sentiment (98/100) contrasts sharply with weak momentum (-10.9% ROC) and oversold conditions (RSI 26), indicating potential misalignment between narrative and technicals. The absence of panic or overconfidence signals a cautious, anchored stance rather than extreme emotional reactions. The key open question is whether traders will hold near support or break away from the anchor under further pressure.
Updated: 09/09/2026, 02:59 PM
What could change this?
👥 What the crowd believes
"New cardiac magnetic resonance imaging data from the Phase 3 ATTRibute-CM study suggested that some acoramidis-treated patients experienced improvements in cardiac structure and function."
"BridgeBio to present new data on the impact of oral infigratinib on medical complications in achondroplasia at ESPE Meeting 2026."
"HC Wainwright & Co. reiterates BridgeBio Pharma with a Buy and maintains $120 price target."
"BridgeBio has entered a voluntary agreement with the U.S. government to expand access to its medicines and lower drug costs."
📈 12D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 100/100
🔴 Weakest match
Jesse Livermore — 20/100
🗣️ Why do they disagree?
This stock divides historical methodologies sharply between those favoring defensive, cyclical, or liquidity-driven approaches and those skeptical of its long-term or fundamental merits. Benjamin Graham and Samuel Nelson both rate it highly—Graham sees it as attractive for a defensive investor, while Nelson highlights a favorable cycle position near oversold territory. Walter Bagehot’s strong liquidity score suggests resilience in downturns, reinforcing a cautious but optimistic stance. However, Fisher, Marks, and Lynch—who prioritize exceptional quality, valuation discipline, or growth differentiation—rank it lower, questioning whether the stock’s price already reflects its potential or if it lacks the standout traits they seek. Meanwhile, Livermore’s low score and Veblen’s critique imply it may lack trend alignment or align with speculative growth patterns, while the efficient-market camp sees little evidence it outperforms passive indexing. The divide reflects a tension between cyclical/defensive value plays and more discerning growth or quality-focused strategies.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 100
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 20%
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 99
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 96
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 76
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 73
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 73
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 65
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 64
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 62
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 61
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 56
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 56
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 55
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 36
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 20
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 10 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
95.8%
Operating Margin
-104.2%
Net Margin
-146.0%
EBITDA Margin
-103.2%
ROE
35.1%
ROA
-78.3%
ROIC
—
EPS
-$3.78
Cash
$570.12M
Total Debt
$2.01B
Current Ratio
2.77
Debt/Equity
-0.96
How is Fair Value calculated? →
Current Price
$66.61
Estimated Fair Value (DCF)
-$67.06
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-200.7%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-558.76M | $-512.62M |
| 2 | 19.4% | $-667.02M | $-561.42M |
| 3 | 13.8% | $-758.73M | $-585.88M |
| 4 | 8.1% | $-820.38M | $-581.18M |
| 5 | 2.5% | $-840.89M | $-546.52M |
Base FCF (last actual year)
$-447.01M
Terminal Value
$-13.26B
Present Value of Terminal Value
$-8.62B
Enterprise Value
$-11.41B
Net Debt
$1.44B
Equity Value
$-12.84B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
-$10.89
Tangible Book Value per Share (Tangible NAV)
-$11.04
Sentiment based on basic keywords (not AI) — 8 positive, 11 neutral, 1 negative out of the last 20 articles.
Yahoo · 18.9.2026
Yahoo · 16.9.2026
SeekingAlpha · 15.9.2026
SeekingAlpha · 10.9.2026
SeekingAlpha · 10.9.2026
Benzinga · 10.9.2026
SeekingAlpha · 9.9.2026
Yahoo · 9.9.2026
Zacks · 9.9.2026
Benzinga · 9.9.2026
Yahoo · 9.9.2026
GlobeNewswire · 9.9.2026
Benzinga · 9.9.2026
Yahoo · 4.9.2026
Insider Monkey · 4.9.2026
Yahoo · 3.9.2026
Zacks · 3.9.2026
Yahoo · 2.9.2026
Benzinga · 2.9.2026
Yahoo · 2.9.2026
BridgeBio Pharma, Inc. (BBIO) currently has a StockIQ AI score of 45/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
BBIO currently scores 45/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, BBIO's estimated fair value is -$67.06, which is 200.7% below the current price of $66.61. This is one valuation model among several signals in the fair-value category, not a price target.
BBIO's technical score is 10/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 126.3%; Operating margin is stable or improving over time; Return on equity (ROE): 35.1% — strong.
Based on the real signals StockIQ computed: Estimated fair value: -$67.06 vs. price $66.61 (-200.7%); Operating margin: -104.2% (negative); Net margin: -146.0% (negative).
StockIQ has no recorded dividend payment history for BBIO.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 10 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Kumar Neil | Open Market Sale | 19.8.2026 | 1,800 | -1,800 | $84.69 |
| Kumar Neil | Open Market Sale | 19.8.2026 | 8,100 | -8,100 | $83.86 |
| Kumar Neil | Open Market Sale | 19.8.2026 | 100 | -100 | $85.65 |
| Kumar Neil | Open Market Sale | 18.8.2026 | 1,900 | -1,900 | $81.15 |
| Kumar Neil | Open Market Sale | 18.8.2026 | 1,199 | -1,199 | $83.77 |
| Kumar Neil | Open Market Sale | 18.8.2026 | 17,279 | -17,279 | $82.21 |
| Kumar Neil | Open Market Sale | 18.8.2026 | 14,602 | -14,602 | $82.99 |
| Apuli Maricel | Tax Withholding in Shares | 16.8.2026 | 4,714 | -4,714 | $79.86 |
| Kumar Neil | Exercise of Derivative Securities | 16.8.2026 | 6,520 | -6,520 | — |
| Kumar Neil | Exercise of Derivative Securities | 16.8.2026 | 11,554 | -11,554 | — |
| Kumar Neil | Exercise of Derivative Securities | 16.8.2026 | 19,599 | -19,599 | — |
| Kumar Neil | Exercise of Derivative Securities | 16.8.2026 | 33,544 | -33,544 | — |
| Kumar Neil | Tax Withholding in Shares | 16.8.2026 | 36,237 | -36,237 | $79.86 |
| Kumar Neil | Exercise of Derivative Securities | 16.8.2026 | 6,520 | +6,520 | — |
| Trimarchi Thomas | Tax Withholding in Shares | 16.8.2026 | 22,781 | -22,781 | $79.86 |
| Kumar Neil | Exercise of Derivative Securities | 16.8.2026 | 19,599 | +19,599 | — |
| Kumar Neil | Exercise of Derivative Securities | 16.8.2026 | 11,554 | +11,554 | — |
| Kumar Neil | Exercise of Derivative Securities | 16.8.2026 | 33,544 | +33,544 | — |
| Apuli Maricel | Open Market Sale | 30.7.2026 | 2,000 | -2,000 | $80.06 |
| Apuli Maricel | Open Market Sale | 30.7.2026 | 127,401 | -2,000 | $80.06 |
| Cook Jennifer E. | Exercise of Derivative Securities | 9.7.2026 | 17,167 | -17,167 | — |
| Cook Jennifer E. | Exercise of Derivative Securities | 9.7.2026 | 19,000 | -19,000 | — |
| Ellis Andrea | Exercise of Derivative Securities | 9.7.2026 | 17,167 | -17,167 | — |
| Cook Jennifer E. | Exercise of Derivative Securities | 9.7.2026 | 112,422 | -112,422 | — |
| Ellis Andrea | Open Market Sale | 9.7.2026 | 17,167 | -17,167 | $84.00 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
21,845,899 shares short as of 2026-08-31 · vs. 23,342,623 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
50.2% of trading volume this week was short selling, vs. 43.1% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology